We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.
Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.
Corporate profile
Press Releases

March 2, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

February 17, 2023: MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders

February 6, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Posters

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
